52 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
-effective paths to market,” added Melissa Tosca, EVP Finance. “For 2024, we expect to increase our R&D spend, with expenses for KIO-301 offset by quarterly … tax credits for the fourth quarter of 2022. The increase in R&D in 2023 was primarily due to greater investment in clinical trial-related activities
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
and partial R&D Cost Refund ("Licensed Technology Access Fee") of [***] sixteen million dollars $16M. The Licensed Technology Fee shall be due and payable
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
9 Nov 23
Results of Operations and Financial Condition
7:01am
impairment of in-process R&D, related to the strategic decision to stop internal development activities leading to commercialization for KIO-101 and KIO-201
FWP
ekklg4umyl0jk
15 May 23
Free writing prospectus
5:18pm
8-K
EX-99.1
hj7mso
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
7yul16gv2oy1n5yer8
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K/A
EX-99.3
h3ozyd tl50
5 Mar 21
Financial Statements and Exhibits
4:15pm